Octreotide Acetate
Pricing Report NDC 25021-455-05
Current Package Pricing Information
The latest wholesale acquisition cost for Octreotide Acetate (NDC 25021-455-05) is $41.75800 per ML. This benchmark price is based on the National Average Drug Acquisition Cost (NADAC) and has been effective since Apr 12, 2017.
As a provided by Sagent Pharmaceuticals, this medication is distributed in a 1 VIAL in 1 CARTON / 5 mL in 1 VIAL configuration. The pricing data is derived from C/I - Chain or Independent Pharmacy surveys, reflecting the actual invoice prices paid by community pharmacies to drug wholesalers.
NADAC Pricing Summary
NADAC pricing snapshot for this package NDC
Acquisition Cost $41.75800 Per ML
The NADAC was calculated based on package size.
Historical Pricing Trends & Acquisition Cost Benchmarks
Since Apr 2014, the NADAC wholesale price for (NDC ) has moved within a range of $41.75800 to $52.17560 per ML. Over this 3 years period, the pricing trend reflects the shifting acquisition costs reported by retail and chain pharmacies to the Centers for Medicare and Medicaid Services (CMS). The following interactive chart and historical table detail every recorded price adjustment based on these federal surveys.
$41.7580 - $52.1756
24.95% Variance
No Change
| Date | Unit Price | Unit | Source | Method | Rate |
|---|---|---|---|---|---|
| Apr 12, 2017 | $41.75800 | ML | C/I - Chain or Independent Pharmacy | Code 4, 5 | G - Generic |
| Oct 19, 2016 | $41.75800 | ML | C/I - Chain or Independent Pharmacy | Code 1, 5 | G - Generic |
| Oct 19, 2016 | $41.75800 | ML | C/I - Chain or Independent Pharmacy | Code 4, 5 | G - Generic |
| Apr 09, 2014 | $52.17560 | ML | C/I - Chain or Independent Pharmacy | Code 4, 5, 6 | G - Generic |
Pricing Methodology Legend
- Code 1: The NADAC was calculated using information from the most recently completed pharmacy survey.
- Code 4: The NADAC was carried forward from the previous file.
- Code 5: The NADAC was calculated based on package size.
- Code 6: The CMS Covered Outpatient File drug category type of S/I/N (Single Source/Innovator/Non-Innovator) has not been applied. Most S/I drugs with the same strength, dosage form and route of administration were grouped together for the purpose of the NADAC calculation and N drugs were also grouped together. In some cases, however, in calculating a NADAC, the CMS S/I/N designation was not applied when the state Medicaid brand or generic payment practices for these drugs generally differed from the CMS Covered Outpatient File designation.
Understanding NADAC Pricing Data
The National Average Drug Acquisition Cost (NADAC) is compiled by the Centers for Medicare and Medicaid Services (CMS). This data is derived from random monthly surveys of more than 60,000 pharmacies across all 50 states.
Important Price Distinction:
The prices listed on this page represent the wholesale invoice price paid by pharmacies to acquire the drug. This is NOT the retail price paid by consumers at the pharmacy counter. Final patient costs typically include pharmacy markups, professional dispensing fees, and insurance adjustments.
NADAC Pricing Data Last Updated on: July 08, 2026
